> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Farxiga Phase 3 Data Show Mortality Benefit
- URL: https://www.fdaweb.com/farxiga-phase-3-data-show-mortality-benefit/
- Published: 2022-08-29T12:00:00.000Z
- Updated: 2026-09-14T17:57:38.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5152613

AstraZeneca says new Phase 3 data on Farxiga (dapagliflozin) demonstrated a mortality benefit compared to placebo in patients with heart failure (HF). These results were presented at the European Society of Cardiology Congress 2022 in Barcelona, Spain and simultaneously published in *Nature Medicine*. “The reduction in risk of cardiovascular (CV) death was consistent across pre-specified subgroups and is the first analysis to demonstrate a mortality benefit with a HF medication in patients with HF across the left ventricular ejection fraction range,” the company says.

The data showed that Farxiga reduced the risk of CV death by 14% over the median follow-up of 22 months, death from any cause by 10%, total (first and repeat) hospitalization for heart failure by 29%, and the composite of death from CV causes, myocardial infarction, or stroke by 10% in patients with HF.

Farxiga is a once-daily SGLT2 inhibitor that was first approved a decade ago for improving glycemic control in adults with Type-2 diabetes.